Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study

[1]  M. Kersten,et al.  CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib , 2017, Haematologica.

[2]  E. Hur,et al.  Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity , 2017, The Journal of Immunology.

[3]  Jun Zhu,et al.  The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages , 2017, Oncotarget.

[4]  S. Brunak,et al.  Integration of Known DNA, RNA and Protein Biomarkers Provides Prediction of Anti-TNF Response in Rheumatoid Arthritis: Results from the COMBINE Study , 2016, Molecular medicine.

[5]  T. Miller,et al.  Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia , 2016, Haematologica.

[6]  A. Deodhar,et al.  Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy , 2015, SpringerPlus.

[7]  Elisa Binda,et al.  High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. , 2014, Rheumatology.

[8]  N. Raje,et al.  A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity , 2014, Leukemia.

[9]  S. Kummerfeld,et al.  Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics , 2014, Arthritis Research & Therapy.

[10]  T. Miller,et al.  Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) , 2013 .

[11]  W. Wilson,et al.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. , 2013, Blood.

[12]  Juswinder Singh,et al.  Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Dougados,et al.  Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. , 2012, Rheumatology.

[14]  C. Geest,et al.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.

[15]  W. Robinson,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells , 2011, Arthritis research & therapy.

[16]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[17]  H. Niiro,et al.  Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.

[18]  D. Gorter.  Bruton’s Tyrosine Kinase and Phospholipase C 2 Mediate Chemokine-Controlled B Cell Migration and Homing , 2008 .

[19]  R. Hendriks,et al.  Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. , 2007, Immunity.

[20]  W. Khan.  Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase , 2001, Immunologic research.